Back

Semaglutide effects on incidence and reoccurrence of atrial fibrillation in the SELECT trial

29 August 2025 (14:30 - 14:40)
Organised by: Logo
Congress Presentation Part of: What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy? Cardiovascular Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Jorge Plutzky

Brigham and Women's Hospital, Boston (United States of America)

5 More presentations in this session

Presentation thumbnail
Effects of oral semaglutide on heart failure outcomes in people with type 2 diabetes and atherosclerotic cardiovascular disease and/or chronic kidney disease participating in SOUL trial
Professor R. Pop-Busui (Portland, US)
Abstract Slides Video
Presentation thumbnail
Vagal activity related events and GLP-1 receptor agonists
Mr A. Holt (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Sodium-Glucose Co-Transporter 2 inhibitors and cardiovascular outcomes: a trial-similar population vs. a broad population
Doctor P. Yazdanfard (Hilleroed, DK)
Abstract Slides Video
Presentation thumbnail
Cardiovascular outcomes in sustained use of glucagon like peptide inhibitors: a trial inspired population vs. a broad population
Ms K. Soerensen (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Effects of SGLT2 inhibitors on triglyceride-derived indices among coronary heart disease patients with varying diabetes control status: a prospective cohort study
Professor N. Wu (Beijing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?
Video

The Event

Event poster

ESC Congress 2025

29 August 2025 14:30 CET
You may be interested in
thumbnail
Congress Session
What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?
thumbnail
Congress Session
Clinical trial updates on the GLP-1 receptor agonist, semaglutide
thumbnail
Congress Presentation
Atrial fibrillation and efficacy of semaglutide 2.4 mg in obesity-related HFpEF: A Patient Level Pooled analysis of STEP-HFpEF and STEP-HFpEF DM trials

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources